These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1229 related articles for article (PubMed ID: 28162094)
21. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Laurberg P; Berman DC; Andersen S; Bülow Pedersen I Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677 [TBL] [Abstract][Full Text] [Related]
22. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084 [TBL] [Abstract][Full Text] [Related]
23. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy. Kung AW; Lau KS; Kohn LD J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791 [TBL] [Abstract][Full Text] [Related]
24. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients. Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435 [TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole. Liu K; Fu Y; Li T; Liu S; Chen D; Zhao C; Shi Y; Cai Y; Yang T; Zheng X Clin Biochem; 2021 Nov; 97():34-40. PubMed ID: 34331946 [TBL] [Abstract][Full Text] [Related]
26. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease. Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621 [TBL] [Abstract][Full Text] [Related]
27. Graves' disease coexisted with resistance to thyroid hormone: a case report. Akahori H; Usuda R J Med Case Rep; 2021 Sep; 15(1):473. PubMed ID: 34560890 [TBL] [Abstract][Full Text] [Related]
28. Development of Graves' hyperthyroidism from primary hypothyroidism in a case of thyroid hemiagenesis. Bando Y; Nagai Y; Ushiogi Y; Toya D; Tanaka N; Fujisawa M Thyroid; 1999 Feb; 9(2):183-7. PubMed ID: 10090320 [TBL] [Abstract][Full Text] [Related]
29. The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease. Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):242-7. PubMed ID: 15314993 [TBL] [Abstract][Full Text] [Related]
30. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661 [TBL] [Abstract][Full Text] [Related]
31. Coexistence of Graves' disease and struma ovarii: case report and literature review. Mimura Y; Kishida M; Masuyama H; Suwaki N; Kodama J; Otsuka F; Kataoka H; Yamauchi T; Ogura T; Kudo T; Makino H Endocr J; 2001 Apr; 48(2):255-60. PubMed ID: 11456276 [TBL] [Abstract][Full Text] [Related]
32. Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report. Cunha FM; Rodrigues E; Oliveira J; Saavedra A; Vinhas LS; Carvalho D J Med Case Rep; 2016 Mar; 10():70. PubMed ID: 27029843 [TBL] [Abstract][Full Text] [Related]
33. A patient-specific treatment model for Graves' hyperthyroidism. Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665 [TBL] [Abstract][Full Text] [Related]
34. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment. Liu X; Shi B; Li H Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949 [TBL] [Abstract][Full Text] [Related]
35. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma. Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384 [TBL] [Abstract][Full Text] [Related]
36. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180 [TBL] [Abstract][Full Text] [Related]
37. Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. Arai N; Inaba M; Ichijyo T; Kagami H; Mine Y J Med Case Rep; 2017 Jan; 11(1):9. PubMed ID: 28061802 [TBL] [Abstract][Full Text] [Related]
38. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. Nachum Z; Rakover Y; Weiner E; Shalev E Am J Obstet Gynecol; 2003 Jul; 189(1):159-65. PubMed ID: 12861156 [TBL] [Abstract][Full Text] [Related]
39. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease. Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111 [TBL] [Abstract][Full Text] [Related]
40. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody. Ochi Y; Kajita Y; Hamazu M; Nagata A Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]